Tumor cell response to synchrotron microbeam radiation therapy differs markedly from cells in normal tissues.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 20510199.
- Also identified by DOI 10.1016/j.ijrobp.2010.01.035.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
High-dose synchrotron microbeam radiation therapy (MRT) can be effective at destroying tumors in animal models while causing very little damage to normal tissues. The aim of this study was to investigate the cellular processes behind this observation of potential clinical importance. MRT was performed using a lattice of 25 mum-wide, planar, polychromatic, kilovoltage X-ray microbeams, with 200-microm peak separation. Inoculated EMT-6.5 tumor and normal mouse skin tissues were harvested at defined intervals post-MRT. Immunohistochemical detection of gamma-H2AX allowed precise localization of irradiated cells, which were also assessed for proliferation and apoptosis. MRT significantly reduced tumor cell proliferation by 24 h post-irradiation (p = 0.002). An unexpected finding was that within 24 h of MRT, peak and valley irradiated zones were indistinguishable in tumors because of extensive cell migration between the zones. This was not seen in MRT-treated normal skin, which appeared to undergo a coordinated repair response. MRT elicited an increase in median survival times of EMT-6.5 and 67NR tumor-inoculated mice similar to that achieved with conventional radiotherapy, while causing markedly less normal tissue damage. This study provides evidence of a differential response at a cellular level between normal and tumor tissues after synchrotron MRT.
Medical subject headings
- Histones
- Mammary Neoplasms, Experimental
- Radiation Injuries, Experimental
- Radiation Tolerance
- Skin
- Synchrotrons